Paxidep CR 12.5 is a controlled-release formulation of paroxetine, a selective serotonin reuptake inhibitor (SSRI) widely recognized for its efficacy in treating complex mood and anxiety disorders. It is frequently prescribed to manage major depressive disorder (MDD), generalized anxiety disorder (GAD), panic disorder, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD). Through gradual release, Paxidep CR 12.5 offers consistent symptom control and enhanced tolerability over time.

- Sleep & Mental Health > Depression, Anxiety, PTSD Paxidep CR 12.5 is commonly used for MDD, GAD, and PTSD. It helps stabilize emotions, alleviate excessive worry, and regulate stress responses. Its effectiveness has been validated in both acute and maintenance phases of treatment. > Obsessive-Compulsive Disorder (OCD) As an FDA-approved SSRI for OCD, paroxetine is effective in reducing repetitive intrusive thoughts and compulsive behaviors, supporting patients in regaining control of daily functioning. > Panic Disorder Paxidep CR 12.5 is widely used to prevent panic attacks and decrease the frequency and intensity of panic episodes. Its controlled-release profile reduces abrupt plasma level fluctuations, minimizing anxiety spikes and improving long-term outcomes.

Paxidep CR 12.5 works by selectively inhibiting the reuptake of serotonin at the neuronal synapse, thereby increasing serotonin levels in the brain. This enhanced serotonergic activity contributes to mood stabilization, decreased anxiety, reduced compulsions, and long-term psychological resilience.

Adult Dosing 1. Depression & MDD - CR: Start 25 mg/day → Maintenance 25–62.5 mg/day → Max 62.5 mg - Increase by 12.5 mg weekly 2. GAD & PTSD - IR: Start 20 mg/day → Maintenance 20–50 mg/day → Max 50 mg - Increase by 10 mg weekly 3. Panic Disorder (PD) - CR: Start 12.5 mg/day → Maintenance 12.5–75 mg/day → Max 75 mg - Increase by 12.5 mg weekly 4. Social Anxiety Disorder (SAD) - CR: Start 12.5 mg/day → Maintenance 12.5–37.5 mg/day → Max 37.5 mg - Increase by 12.5 mg weekly 5. PMDD (CR Only) - Continuous: 12.5–25 mg/day - Cyclic: 12.5 mg/day, 14 days pre-menses → stop day 1 of menses 6. OCD - IR: Start 20 mg/day → Maintenance 20–60 mg/day → Max 60 mg - Increase by 10 mg weekly 7. Menopausal Symptoms - Mesylate: 7.5 mg/day (not for psychiatric conditions) Geriatric Dosing 1. Depression & MDD - CR: Start 12.5 mg/day → Maintenance 12.5–50 mg/day → Max 50 mg 2. GAD, PTSD, OCD, SAD - IR: Start 10 mg/day → Maintenance 10–40 mg/day → Max 40 mg 3. Panic Disorder (PD) - CR: Start 12.5 mg/day → Maintenance 12.5–50 mg/day → Max 50 mg

Store below 30°C in a cool, dry place. Keep the tablets in their original packaging, protected from moisture and direct sunlight. Do not freeze. Keep out of reach of children and pets.

Common side effects include nausea, headache, dizziness, dry mouth, drowsiness, and delayed ejaculation. Some users may experience weight gain, increased sweating, or sexual dysfunction. Rare but serious reactions include serotonin syndrome, suicidal ideation in younger patients, and withdrawal symptoms upon abrupt cessation. Always taper under medical guidance.